2024 - 2032 年局部藥物 CDMO 市場機會、成長動力、產業趨勢分析與預測

Topical Drugs CDMO Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 - 2032

出版日期: 2024年10月30日 | 出版商:

Global Market Insights Inc. | 英文 140 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2023 年，全球外用藥物CDMO 市場達到437 億美元，預計2024 年至2032 年複合年成長率為10.5%。輸送系統為傳統藥物輸送系統提供了更安全、更方便的替代品。隨著患者和醫療保健提供者尋求能夠以最小的全身影響進行有針對性的局部治療的解決方案，包括乳膏、凝膠、軟膏和經皮貼劑在內的局部製劑越來越受到關注。製藥公司擴大將這些特殊藥物的開發和製造外包給CDMO，後者提供必要的專業知識、先進的製造技術和監管合規性，使它們能夠有效地滿足外用藥物生產不斷變化的需求。市場按產品類型分為半固體、液體、經皮和固體製劑，其中半固體製劑處於領先地位，2023年將達到273億美元。和凝膠，它們已成為治療多種皮膚病的核心。

半固體製劑擅長將活性藥物成分直接輸送到受影響區域，使其在局部治療中非常有效，同時減少全身吸收，在皮膚病學中尤其有價值。在治療應用方面，外用藥物CDMO市場分為皮膚科、疼痛管理、傷口護理和眼科等關鍵領域。由於皮膚病的流行和對有效治療的需求，皮膚科是最大的細分市場，到 2023 年將佔據 34.5% 的市場。痤瘡、濕疹和牛皮癬等皮膚病影響著全世界數百萬人，推動了對能夠快速緩解症狀的創新局部治療的需求。

外用藥物在皮膚科中特別受重視，因為它們能夠將活性成分直接輸送到受影響的區域，限制全身暴露並最大限度地減少副作用。美國外用藥物 CDMO 市場預計將以 10.1% 的複合年成長率成長，到 2032 年將達到 350 億美元，在這一全球擴張中發揮關鍵作用。該國受益於 CDMO 的強大存在，它們與製藥公司密切合作，最佳化開發和製造流程，以加快新配方的上市時間。這些合作關係不僅簡化了生產，還提高了產品品質和永續性，滿足了對高效、環保的護膚解決方案日益成長的需求。

市場範圍
開始年份	2023年
預測年份	2024-2032
起始值	437 億美元
預測值	1059 億美元
複合年成長率	10.5%

The Global Topical Drugs CDMO Market reached USD 43.7 billion in 2023 and is projected to grow at 10.5% CAGR from 2024 to 2032. This expansion is fueled by a rising demand for non-invasive drug delivery systems that offer safer and more convenient alternatives to traditional oral and injectable therapies. Topical formulations, including creams, gels, ointments, and transdermal patches, are gaining traction as patients and healthcare providers seek solutions that allow targeted, localized treatment with minimal systemic impact. Pharmaceutical companies are increasingly outsourcing the development and manufacturing of these specialized drugs to CDMOs, which provide essential expertise, advanced manufacturing technology, and regulatory compliance, allowing them to effectively meet the evolving demands of topical drug production. The market is segmented by product type into semi-solid, liquid, transdermal, and solid formulations, with semi-solid formulations leading the way, accounting for USD 27.3 billion in 2023. This segment includes various types of applications such as creams, ointments, and gels, which have become central to the treatment of numerous dermatological conditions.

Semi-solid formulations excel in delivering active pharmaceutical ingredients directly to affected areas, making them highly effective in localized treatments with reduced systemic absorption, especially valuable in dermatology. In terms of therapeutic applications, the topical drugs CDMO market is divided into key areas such as dermatology, pain management, wound care, and ophthalmology. Dermatology is the largest segment, holding 34.5% of the market share in 2023, driven by the prevalence of skin disorders and the need for effective treatments. Skin conditions, including acne, eczema, and psoriasis, impact millions worldwide, propelling the demand for innovative topical treatments that offer rapid relief.

Topical drugs are particularly valued in dermatology for their ability to deliver active ingredients directly to the affected areas, limiting systemic exposure and minimizing side effects. The U.S. topical drugs CDMO market, projected to grow at a 10.1% CAGR and reach USD 35 billion by 2032, plays a pivotal role in this global expansion. The country benefits from a strong presence of CDMOs collaborating closely with pharmaceutical companies, optimizing development and manufacturing processes to expedite time-to-market for new formulations. These partnerships not only streamline production but also enhance product quality and sustainability, aligning with the increasing demand for efficient and eco-friendly skincare solutions.

Market Scope
Start Year	2023
Forecast Year	2024-2032
Start Value	$43.7 Billion
Forecast Value	$105.9 Billion
CAGR	10.5%

Chapter 1 Methodology & Scope

1.1 Market scope & definition
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing prevalence of skin disorder across the globe
  - 3.2.1.2 Growing adoption of outsourcing of manufacturing activities
  - 3.2.1.3 Growing aging population
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Challenges in quality control
  - 3.2.2.2 High capital investment
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Porter's analysis
3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Semi-solid formulations
- 5.2.1 Creams
- 5.2.2 Ointments
- 5.2.3 Gels
- 5.2.4 Other semi-solid formulations
5.3 Liquid formulations
5.4 Transdermal patches
5.5 Solid formulations

Chapter 6 Market Estimates and Forecast, By Therapeutic Area, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Dermatology
6.3 Pain management
6.4 Wound care
6.5 Ophthalmology
6.6 Other therapeutic areas

Chapter 7 Market Estimates and Forecast, By Service Type, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Contract manufacturing
7.3 Contract development

Chapter 8 Market Estimates and Forecast, By End Use, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Pharmaceutical companies
8.3 Biotechnology companies
8.4 Other end users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE